Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This micro-cap stock is leading the US graphite revolution (click to learn more) Eric Sprott Announces Changes to His Holdings in Honey Badger Silver Inc. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Opthea Ltd (PK) CKDXF

Alternate Symbol(s):  OPTEY

Healthcare Biotechnology
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME... see more

Recent & Breaking News (PINL:CKDXF)

Opthea Provides Corporate Update

GlobeNewswire August 18, 2025

Opthea Announces Decision to Discontinue Wet AMD Trials

GlobeNewswire March 31, 2025

Opthea Announces COAST Phase 3 Trial Topline Results

GlobeNewswire March 24, 2025

Opthea Announces Phase 2b Wet AMD Publication

GlobeNewswire March 3, 2025

Opthea Reports Half Year Results and Business Updates

GlobeNewswire February 28, 2025

Opthea Completes Drug Product PPQ Campaign

GlobeNewswire February 26, 2025

Opthea Completes COAST Final Week 52 Patient Visit

GlobeNewswire February 18, 2025

Opthea to Present at Oppenheimer Healthcare Conference

GlobeNewswire February 7, 2025

Opthea Wet AMD Data Featured at Macula Society Meeting

GlobeNewswire February 6, 2025

Opthea to Host Investor Days in New York and Australia

GlobeNewswire January 8, 2025

Opthea Announces Publication in Diabetic Macular Edema

GlobeNewswire January 7, 2025

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 19, 2024

Opthea's Wet AMD Program to be Featured at FLORetina 2024

GlobeNewswire November 26, 2024

Opthea to Participate in Citi 2024 Global Healthcare Conference

GlobeNewswire November 25, 2024

Opthea Appoints Kathy Connell to Board of Directors

GlobeNewswire November 15, 2024

Opthea's Wet AMD Program Featured at Ophthalmology Events

GlobeNewswire November 12, 2024

Opthea to Participate in November Investor Conferences

GlobeNewswire November 4, 2024

Opthea Files Notice of Annual General Meeting

GlobeNewswire October 16, 2024

Opthea Wet AMD Program to be Presented at Innovate Retina

GlobeNewswire October 10, 2024

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

GlobeNewswire October 8, 2024

Podcasts